Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
Delcath Systems to Host Third Quarter 2025 Earnings Call
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.